—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Revolution Medicines Inc (RVMD) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for RVMD, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 57/100 · S&P 500 fund at 60, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-02
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +7.5% over 20 sessions. Factor regime → 2026-10-05
  • Sector × region Health care in US: −2.6% week · −3.5% month · +3.0% quarter · +14.3% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-04
  • Sovereign pressure Index 0.96 · up 0.53 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-05
How it trades on rate days beta 0.97 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How RVMD has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.97 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Revolution Medicines Inc moved 0.97% on average · correlation 0.14 · higher than 86% of US names
  • Beta, last 3 months 0.37 less rate-sensitive lately than over the year
  • On the 10 worst bond days −1.40% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +4.78% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against RVMD on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Revolution Medicines Inc

RVMD in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Revolution Medicines is a clinical-stage biotechnology company that designs drugs for cancers driven by mutated RAS proteins. Its lead candidate, daraxonrasib, sits in a late-stage trial for first-line pancreatic cancer alongside a second RAS-targeting compound, zoldonrasib. Other candidates in its pipeline aim at different RAS mutations found in solid tumours. The company has no approved product yet and is based in Redwood City, California.
Where it sits in the stack
Revolution Medicines holds no seat in our index; it belongs to the biotech sleeve of the Healthcare sector we track, where the diary follows trial-stage drug developers for pipeline readouts rather than product sales.
Who it is priced against
Closelooknet's peer group places it among scored Healthcare names in the US — argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics — because they share sector and country. The market also names Amgen, whose approved RAS inhibitor competes with the company's pipeline.
Why Closelooknet tracks it
It carries a Closelooknet score, our sector-neutral read across six modules, though it holds no index seat. Momentum reads strongest and quality reads weakest of those modules. The diary has not yet quoted the name in an edition.
What the diary watches
The diary watches how the phase 3 trial combining daraxonrasib and zoldonrasib in pancreatic cancer reads out, since a clinical result would move momentum and quality readings together.

Revolution Medicines Inc (RVMD) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 30/100 composite (momentum 87, quality 1, valuation —) across 6 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 6 analyst actions on the wire · latest: initiation by Brookline Capital, 2026-09-28

The Street on this name

Analyst actions and the latest print for RVMD from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Initiation Brookline Capital — at Buy Initiated to Buy 2026-09-28
  • Price target Needham — target 275 from 240 Target raised to $275 from $240 (+32.3% to spot) 2026-08-31
  • Price target Guggenheim — target 275 from 240 Target raised to $275 from $240 (+24.3% to spot) 2026-08-28

6 actions on the analyst wire since 2026-08-13: 1 initiation, 5 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months · buybacks 8 m USD in FY2025

Dividends and capital return

What RVMD pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 8 m USD 0.0% of today's market value
  • Share count +13.3% in FY2025 118 m USD of stock-based compensation in the year
  • Capital returned 8 m USD in a year of negative free cash flow dividends and buybacks together

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-06

Quick answers

What is Revolution Medicines Inc (RVMD)?

Revolution Medicines Inc trades as RVMD on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-06.

Is RVMD in a Closelooknet index?

Not currently — Revolution Medicines Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-06.

What is Revolution Medicines Inc's Closelooknet composite score?

30 out of 100, with momentum 87, quality 1 and valuation n/a sub-scores, as of 2026-10-06. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does RVMD trade against its moving averages?

Uptrend stack intact: Trades +2.4% vs the 50-day and +41.7% vs the 200-day average, 7.4% below the 52-week high and +354.2% off the 52-week low. Computed from daily closes. As of 2026-10-05 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Revolution Medicines Inc compare with its peers?

Against its peer group (Biotechnology · US), Revolution Medicines Inc (RVMD) sits 7.4% below its 52-week high, 2.4% above its 50-day average; BeiGene, Ltd. (ONC) is 6.1% below, Caris Life Sciences, Inc. Common Stock (CAI) is 9.7% below, Protagonist Therapeutics Inc (PTGX) is 12.5% below. Put any of them next to RVMD in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Revolution Medicines Inc trade when bond yields rise?

Over the past year Revolution Medicines Inc had a beta of 0.97 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 86% of US names. On the 10 sessions in which long bonds fell most it moved −1.40% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Revolution Medicines Inc do?

Revolution Medicines is a clinical-stage biotechnology company that designs drugs for cancers driven by mutated RAS proteins. Its lead candidate, daraxonrasib, sits in a late-stage trial for first-line pancreatic cancer alongside a second RAS-targeting compound, zoldonrasib. Other candidates in its pipeline aim at different RAS mutations found in solid tumours. Closelooknet's peer group places it among scored Healthcare names in the US — argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics — because they share sector and country. The market also names Amgen, whose approved RAS inhibitor competes with the company's pipeline.

Where does Revolution Medicines Inc sit in the AI build-out?

Revolution Medicines holds no seat in our index; it belongs to the biotech sleeve of the Healthcare sector we track, where the diary follows trial-stage drug developers for pipeline readouts rather than product sales. It carries a Closelooknet score, our sector-neutral read across six modules, though it holds no index seat. Momentum reads strongest and quality reads weakest of those modules. The diary has not yet quoted the name in an edition.

Does Revolution Medicines Inc pay a dividend?

No cash distribution shows in Revolution Medicines Inc’s price series over the last three years. In fiscal 2025 the company bought back 8 m USD of its own shares. The share count rose 13.3% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Revolution Medicines Inc recently?

The most recent analyst action on Revolution Medicines Inc on the Closelooknet wire is a initiation by Brookline Capital on 2026-09-28 (at Buy). 6 actions on the analyst wire since 2026-08-13: 1 initiation, 5 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for RVMD, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.